Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages

  Allonen, Jaakko ^a   Nieminen, Markku S ^a   Lokki, Maisa ^b   Parkkonen, Olavi ^a   Vaara, Satu ^a   Perola, Markus ^c   Hiekkalinna, Tero ^c,d   Strandberg, Timo E ^e   Sinisalo, Juha ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PATIENT COMPLIANCE; PRESCRIPTION; PROSPECTIVE STUDY;

EID: 84869506427     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22056     Document Type: Article

References (30)

1. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007; 11: 1-160.
2. Van de Werf F, Bax J, Betriu A, et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008; 29: 2909-2945.
3. Waters DD, Ku I., Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol. 2009; 54: 1434-1437.
4. Karter AJ, Parker MM, Moffet HH, et al. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009; 44 (5 part 1): 1640-1661.
5. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288: 455-461. (Pubitemid 34787476)
6. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nationwide register study in Finland. Clin Ther. 2008;30(part 2): 2228-2240.
7. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279: 1458-1462. (Pubitemid 28228203)
8. Blackburn DF, Dobson RT, Blackburn JL, et al. Adherence to statins, β-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005; 21: 485-488. (Pubitemid 40823600)
9. West of Scotland Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997; 18: 1718-1724.
10. McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother. 2007; 41: 1805-1811. (Pubitemid 350044342)
11. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med. 2009; 169: 260-268.
12. Jackevicius CA, Anderson GM, Leiter L, et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001; 161: 183-188. (Pubitemid 32102385)
13. Jackevicius CA, Mamdani M, Tu JV., Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288: 462-467. (Pubitemid 34787477)
14. Vaara S, Nieminen MS, Lokki M-L, et al. Cohort Profile: the Corogene study. Int J Epidemiol 2011; doi:10.1093/ije/dyr090.
15. Bassand JP, Hamm CW, Ardissino D, et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28: 1598-1660. (Pubitemid 47227122)
16. Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010; 16: 116-122.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
18. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005;366:1358 and Lancet. 2008;371:2084]. Lancet. 2005; 366: 1267-1278.
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-1357.
20. Cooke CA, Kirkland SA, Sketris IS, et al. The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. BMC Health Serv Res. 2009; 9: 198.
21. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333: 15.
22. Hippisley-Cox J, Coupland C., Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. Heart. 2006; 92: 752-758. (Pubitemid 43799205)
23. Ab E, Denig P, van Vliet T, et al. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract. 2009; 10: 24.
24. Ohlsson H, Merlo J., Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type? â€"a multilevel logistic regression analysis in South Sweden. Pharmacoepidemiol Drug Saf. 2009; 18: 682-690.
25. Cohen SM, Kataoka-Yahiro M., Provider adherence to clinical guidelines related to lipid-lowering medications. Mil Med. 2010; 175: 122-126.
26. Jackevicius CA, Li P, Tu JV., Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008; 117: 1028-1036.
27. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004; 19: 638-645.
28. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335: 1001-1009. (Pubitemid 26338729)
29. McDermott MM, Schmitt B, Wallner E., Impact of medication nonadherence on coronary heart disease outcomes: a critical review. Arch Intern Med. 1997; 157: 1921-1929. (Pubitemid 27398356)
30. Dragomir A, Côté R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010; 13: 87-94.